Home » J&J’s Antibiotic Drug Levaquin Gains a Dozen Generic Competitors
J&J’s Antibiotic Drug Levaquin Gains a Dozen Generic Competitors
The FDA announced the first approvals of generic versions of Johnson & Johnson’s (J&J) blockbuster antibiotic Levaquin, as the product loses its exclusivity. Levaquin (levofloxacin) garnered $1.4 billion in sales for J&J last year.
Generic Line
Generic Line
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May